Institutional ticker directory tracking stock mentions, long/short ideas, and high-conviction pitches extracted from quarterly hedge fund letters.
| Ticker | Company | Sector | Industry | Pitches | Stance |
|---|---|---|---|---|---|
| Fund / Manager | Thesis Excerpt | Stance | Period / Date | Action |
|---|---|---|---|---|
Janus Henderson Forty Fund Nick Schommer, Brian Recht | “Madrigal Pharmaceuticals was a relative contributor as the company continued to establish leadership in the treatment of metabolic dysfunction-associated steatohepatitis (MASH). The firm has seen very strong sales of Rezdiffra, the first FDA-approved medication for MASH that targets liver fat accumulation and inflammation. Sentiment around the drug has been positive, supported by strong physician adoption and favorable payer reception trends. These early commercial indicators reinforced confidence in Madrigal's growth potential. BSD Analysis: Madrigal is a pure-play bet on NASH treatment finally becoming real medicine rather than perpetual disappointment. Its lead asset targets a massive unmet need with no approved alternatives. Clinical data credibility is the core asset here. Commercial execution and reimbursement will define the next phase. Investors price binary outcomes aggressively. If adoption materializes, revenue ramps fast. If not, downside is obvious. This is biotech asymmetry, not diversification. Science decides everything.” | BULL | Q4 2025 Dec 31, 2025 | View Pitch |
Meridian Growth Fund ArrowMark Colorado Holdings, LLC | “Madrigal Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a non-alcoholic liver disease with a high unmet medical need. The stock performed well on evidence of a very strong commercial launch and execution of Rezdiffra, a new drug therapy that has put Madrigal on an annualized pace for more than $1 billion in new sales this year. With U.S. market penetration in the single digits, the therapy has the potential to grow into a multi-billion-dollar blockbuster over time. In addition, the company in-licensed an oral GLP-1 drug, and additional therapies in the pipeline also show promise of incremental growth. During the period, we trimmed our position as the share price appreciated, based on our valuation discipline. :contentReference[oaicite:13]{index=13} BSD Analysis: MDGL's first-mover advantage in MASH plus expanding label/adjacent assets support multi-year growth. Early launch metrics de-risk forecasts; balance sheet optionality enables pipeline build-out. Valuation rich but justified if penetration expands.” | BEAR | Q3 2025 Sep 30, 2025 | View Pitch |
Artisan Partners Small Cap Fund Jay Warner | “Madrigal Pharmaceuticals is a commercial-stage biotechnology company focused on treating metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need. Madrigal's lead drug, RezdiffraTM, is the first and only FDA-approved medication to target liver fibrosis, demonstrating high efficacy with minimal side effects. Given the significant failure rates of previous treatments for this condition, we are confident in the company's ability to maintain a competitive edge and further differentiate itself in the market. Additionally, there is potential to expand its application to more advanced stages of liver fibrosis. BSD Analysis: Madrigal's leadership in MASH positions it for rapid revenue scaling as the first approved therapy in a massive underserved market. Rezdiffra's efficacy profile supports significant pricing power and potential label expansion. While the valuation is elevated, biotech comps suggest further upside if early launch metrics exceed expectations. Key risks include reimbursement dynamics and competitive entrants.” | BULL | Q2 2025 Jul 22, 2025 | View Pitch |
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.
